Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Kelesitse Phiri"'
Autor:
Alexander Slowley, Kelesitse Phiri, Jasjit K. Multani, Vicky Casey, Sheila Mpima, Marie Yasuda, Chi‐Chang Chen, Fil Manuguid, Jessica Chao, Amine Aziez, Kelly F. Bell, Alexander Stojadinovic
Publikováno v:
Thoracic Cancer, Vol 14, Iss 28, Pp 2846-2858 (2023)
Abstract Background Real‐world evidence is increasingly used to guide treatment and regulatory decisions for non‐small cell lung cancer (NSCLC). Real‐world treatment patterns and clinical outcomes among patients with advanced/metastatic NSCLC i
Externí odkaz:
https://doaj.org/article/2bafcf605a8c49ab901542b701ab65ea
Autor:
Sophia Junker, Alexander Slowley, Joachim Göthert, Tim D’estrube, Kelesitse Phiri, Martin Krammer, Lena Sofie Weinmann, Florian Karl, Suzanne Landi, Sabrina Müller, Boris Gorsh
Publikováno v:
HemaSphere, Vol 7, p e32222e6 (2023)
Externí odkaz:
https://doaj.org/article/ddd63fbea82f488a9ad249b95590ce26
Autor:
Andrea K. Chomistek, Kelesitse Phiri, Michael C. Doherty, Jenna F. Calderbank, Stephanie E. Chiuve, Brenda Hinman McIlroy, Michael C. Snabes, Cheryl Enger, John D. Seeger
Publikováno v:
Drug Safety. 46:209-222
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36266a9d0e5b874003e36741cc78dd93
https://doi.org/10.1007/s40264-022-01261-5
https://doi.org/10.1007/s40264-022-01261-5
Autor:
Xuezheng Sun, Nicholas Ballew, Linda Kalilani, Kelesitse Phiri, Kelly Bell, Alexander Slowly, Magdalena Zajac, Erin Hofstatter, Angela Silvestro, Zebin Wang, Jeanne Schilder
Publikováno v:
Cancer Research. 83:6695-6695
Background: Circulating tumor DNA (ctDNA) has been increasingly used in the clinical care of patients with cancer. This systematic review summarizes current data on the utility of ctDNA in breast cancer clinical research and practice and provides ins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e94bfcca85863a1fa0f5c602d4c568a2
https://doi.org/10.1158/1538-7445.am2023-6695
https://doi.org/10.1158/1538-7445.am2023-6695
Autor:
Andrea K. Chomistek, Kelesitse Phiri, Michael C. Doherty, Jenna F. Calderbank, Stephanie E. Chiuve, Brenda Hinman McIlroy, Michael C. Snabes, Cheryl Enger, John D. Seeger
Publikováno v:
Drug Safety. 46:515-515
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ced12196984a4d180fc494663a4789d7
https://doi.org/10.1007/s40264-023-01280-w
https://doi.org/10.1007/s40264-023-01280-w
Autor:
Monica L. Bertoia, Kelesitse Phiri, C. Robin Clifford, Michael Doherty, Li Zhou, Laura T. Wang, Natalie A. Bertoia, Florence T. Wang, John D. Seeger
Publikováno v:
Pharmacoepidemiology and drug safety. 31(8)
Health care insurance claims databases are becoming a more common data source for studies of medication safety during pregnancy. While pregnancies have historically been identified in such databases by pregnancy outcomes, International Classification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a59263e899e0393e35864007e12c781
https://pubmed.ncbi.nlm.nih.gov/35622900
https://pubmed.ncbi.nlm.nih.gov/35622900
Autor:
Modiegi Diseko, Shahin Lockman, Tumalano Sekoto, Roger L. Shapiro, Kelesitse Phiri, George R. Seage, Joseph Makhema, Gloria Mayondi, Christina Fennell, Mompati Mmalane, Rebecca Zash
Publikováno v:
J Pediatric Infect Dis Soc
Background Women with vertically acquired HIV (VHIV) may have a greater risk of adverse birth outcomes than women with horizontally acquired HIV (HHIV). Methods The Tsepamo study performed birth outcomes surveillance at 8 government delivery sites in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::305ef13b9e34c9e5f93a55597274f22d
https://doi.org/10.1093/jpids/piaa051
https://doi.org/10.1093/jpids/piaa051
Autor:
Cheryl Enger, Libby Horter, Nina Sahlertz Kristiansen, Stefan de Vogel, Kelesitse Phiri, Brandon T. Suehs, Jesper Hallas, Alejandro Arana, Marie Linder, Ingvild Odsbu, Yihua Xu, Andrea V. Margulis, Kwame Appenteng, John D. Seeger, Morten Olesen, Veena Hoffman, Susana Perez-Gutthann
Publikováno v:
Hoffman, V, Hallas, J, Linder, M, Margulis, A, Suehs, B T, Arana, A, Phiri, K, Enger, C, Horter, L, Odsbu, I, Olesen, M, Perez-Gutthann, S, Xu, Y, Kristiansen, N S, Appenteng, K, de Vogel, S, Seeger, J D & the mirabegron PMR-PASS study group 2021, ' Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder : Findings from a Non-Interventional, Multinational, Cohort Study ', Drug Safety, vol. 44, no. 8, pp. 899-915 . https://doi.org/10.1007/s40264-021-01095-7
Drug Safety
Drug Safety
Introduction During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased vital signs vs placebo in patients with overactive bladder. Objective The purpose of this study was to compare incidence rates of adverse car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::606ed98949016a3becf28423411ba054
https://findresearcher.sdu.dk:8443/ws/files/191412893/Hoffman2021_Article_CardiovascularRiskInUsersOfMir.pdf
https://findresearcher.sdu.dk:8443/ws/files/191412893/Hoffman2021_Article_CardiovascularRiskInUsersOfMir.pdf
Autor:
John D. Seeger, Marie Linder, Veena Hoffman, Alejandro Arana, Shahram Bahmanyar, Susana Perez-Gutthann, Jesper Hallas, Libby Horter, Brandon T. Suehs, Stefan de Vogel, Kelesitse Phiri, Nina Sahlertz Kristiansen, Andrea V. Margulis, Ingvild Odsbu, Kwame Appenteng, Cheryl Enger, Morten Olesen
Publikováno v:
Phiri, K, Hallas, J, Linder, M, Margulis, A, Suehs, B, Arana, A, Bahmanyar, S, Hoffman, V, Enger, C, Horter, L, Odsbu, I, Olesen, M, Perez-Gutthann, S, Kristiansen, N S, Appenteng, K, de Vogel, S & Seeger, J 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion, vol. 37, no. 5, pp. 867-877 . https://doi.org/10.1080/03007995.2021.1891035
the Mirabegron PMR-PASS study group 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion . https://doi.org/10.1080/03007995.2021.1891035
the Mirabegron PMR-PASS study group 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion . https://doi.org/10.1080/03007995.2021.1891035
Objective: This post-authorization safety study (EU PAS Register Number: EUPAS16088) was designedto compare the incidence of cancer outcomes in patients treated with mirabegron versus antimuscarinicmedications.Methods: Cohorts of mirabegron initiator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e16fdb16219dfcf888757ab899a0540
https://pubmed.ncbi.nlm.nih.gov/33591859
https://pubmed.ncbi.nlm.nih.gov/33591859
Autor:
Stefan de Vogel, Andrea V. Margulis, Alejandro Arana, Libby Horter, Susana Perez-Gutthann, Kwame Appenteng, Kelesitse Phiri, Shahram Bahmanyar, Jesper Hallas, Morten S. Olesen, Nina Sahlertz Kristiansen, John D. Seeger, Marie Linder, Cheryl Enger, Ingvild Odsbu, Brandon T. Suehs
Publikováno v:
The Journal of Urology. 203:e910-e911
INTRODUCTION AND OBJECTIVE:The β3-adrenergic agonist mirabegron is an alternative to antimuscarinics (AMs) for treatment of overactive bladder. During mirabegron development, a greater number of ca...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::558b6ac186b66a3ee986d4f7837f7a00
https://doi.org/10.1097/ju.0000000000000931.010
https://doi.org/10.1097/ju.0000000000000931.010